Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF
Paul F Mercer, Hannah V Woodcock, Jessica D Eley, Manuela Platé, Michal G Sulikowski, Pascal F Durrenberger, Linda Franklin, Carmel B Nanthakumar, Yim Man, Federica Genovese, Robin J McAnulty, Shuying Yang, Toby M Maher, Andrew G Nicholson, Andy D Blanchard, Richard P Marshall, Pauline T Lukey, Rachel C Chambers, Paul F Mercer, Hannah V Woodcock, Jessica D Eley, Manuela Platé, Michal G Sulikowski, Pascal F Durrenberger, Linda Franklin, Carmel B Nanthakumar, Yim Man, Federica Genovese, Robin J McAnulty, Shuying Yang, Toby M Maher, Andrew G Nicholson, Andy D Blanchard, Richard P Marshall, Pauline T Lukey, Rachel C Chambers
Abstract
Rationale: Idiopathic pulmonary fibrosis (IPF) is the most rapidly progressive and fatal of all fibrotic conditions with no curative therapies. Common pathomechanisms between IPF and cancer are increasingly recognised, including dysfunctional pan-PI3 kinase (PI3K) signalling as a driver of aberrant proliferative responses. GSK2126458 is a novel, potent, PI3K/mammalian target of rapamycin (mTOR) inhibitor which has recently completed phase I trials in the oncology setting. Our aim was to establish a scientific and dosing framework for PI3K inhibition with this agent in IPF at a clinically developable dose.
Methods: We explored evidence for pathway signalling in IPF lung tissue and examined the potency of GSK2126458 in fibroblast functional assays and precision-cut IPF lung tissue. We further explored the potential of IPF patient-derived bronchoalveolar lavage (BAL) cells to serve as pharmacodynamic biosensors to monitor GSK2126458 target engagement within the lung.
Results: We provide evidence for PI3K pathway activation in fibrotic foci, the cardinal lesions in IPF. GSK2126458 inhibited PI3K signalling and functional responses in IPF-derived lung fibroblasts, inhibiting Akt phosphorylation in IPF lung tissue and BAL derived cells with comparable potency. Integration of these data with GSK2126458 pharmacokinetic data from clinical trials in cancer enabled modelling of an optimal dosing regimen for patients with IPF.
Conclusions: Our data define PI3K as a promising therapeutic target in IPF and provide a scientific and dosing framework for progressing GSK2126458 to clinical testing in this disease setting. A proof-of-mechanism trial of this agent is currently underway.
Trial registration number: NCT01725139, pre-clinical.
Keywords: Idiopathic pulmonary fibrosis.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Figures
References
- Lee AS, Mira-Avendano I, Ryu JH, et al. . The burden of idiopathic pulmonary fibrosis: an unmet public health need. Respir Med 2014;108:955–67. 10.1016/j.rmed.2014.03.015
- Richeldi L, du Bois RM, Raghu G, et al. . Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071–82. 10.1056/NEJMoa1402584
- King TE Jr, Bradford WZ, Castro-Bernardini S, et al. . A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083–92. 10.1056/NEJMoa1402582
- Datta A, Scotton CJ, Chambers RC. Novel therapeutic approaches for pulmonary fibrosis. Br J Pharmacol 2011;163:141–72. 10.1111/j.1476-5381.2011.01247.x
- Akhurst RJ, Hata A. Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov 2012;11:790–811. 10.1038/nrd3810
- Horan GS, Wood S, Ona V. , et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med 2008;177:56–65. 10.1164/rccm.200706-805OC
- Parker MW, Rossi D, Peterson M, et al. . Fibrotic extracellular matrix activates a profibrotic positive feedback loop. J Clin Invest 2014;124:1622–35. 10.1172/JCI71386
- Daniels CE, Jett JR. Does interstitial lung disease predispose to lung cancer? Curr Opin Pulm Med 2005;11:431–7. 10.1097/
- Rabinovich EI, Kapetanaki MG, Steinfeld I, et al. . Global methylation patterns in idiopathic pulmonary fibrosis. PLoS ONE 2012;7:e33770 10.1371/journal.pone.0033770
- Selman M, Pardo A. Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. an integral model. Am J Respir Crit Care Med 2014;189:1161–72. 10.1164/rccm.201312-2221PP
- Vancheri C. Common pathways in idiopathic pulmonary fibrosis and cancer. Eur Respir Rev 2013;22:265–72. 10.1183/09059180.00003613
- Groves AM, Win T, Screaton NJ. , et al. Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG PET/CT. J Nucl Med 2009;50:538–45. 10.2967/jnumed.108.057901
- Vanhaesebroeck B, Guillermet-Guibert J, Graupera M. , et al. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010;11:329–41. 10.1038/nrm2882
- Conte E, Gili E, Fruciano M. , et al. PI3K p110γ overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: in vitro effects of its inhibition. Lab Invest 2013;93:566–76. 10.1038/labinvest.2013.6
- Horowitz JC, Lee DY, Waghray M. , et al. Activation of the pro-survival phosphatidylinositol 3-kinase/AKT pathway by transforming growth factor-beta1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor. J Biol Chem 2004;279:1359–67. 10.1074/jbc.M306248200
- Kavanaugh WM, Klippel A, Escobedo JA. , et al. Modification of the 85-kilodalton subunit of phosphatidylinositol-3 kinase in platelet-derived growth factor-stimulated cells. Mol Cell Biol 1992;12:3415–24. 10.1128/MCB.12.8.3415
- White ES, Atrasz RG, Hu B. , et al. Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10). Am J Respir Crit Care Med 2006;173:112–21. 10.1164/rccm.200507-1058OC
- Xia H, Diebold D, Nho R. , et al. Pathological integrin signaling enhances proliferation of primary lung fibroblasts from patients with idiopathic pulmonary fibrosis. J Exp Med 2008;205:1659–72. 10.1084/jem.20080001
- Conte E, Fruciano M, Fagone E, et al. . Inhibition of PI3K prevents the proliferation and differentiation of human lung fibroblasts into myofibroblasts: the role of class I P110 isoforms. PLoS ONE 2011;6:e24663 10.1371/journal.pone.0024663
- Le Cras TD, Korfhagen TR, Davidson C. , et al. Inhibition of PI3K by PX-866 prevents transforming growth factor-alpha-induced pulmonary fibrosis. Am J Pathol 2010;176:679–86. 10.2353/ajpath.2010.090123
- Knight SD, Adams ND, Burgess JL. , et al. Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin. ACS Med Chem Lett 2010;1:39–43. 10.1021/ml900028r
- Raghu G, Collard HR, Egan JJ. , et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788–824. 10.1164/rccm.2009-040GL
- Keerthisingam CB, Jenkins RG, Harrison NK. , et al. Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 2001;158:1411–22. 10.1016/S0002-9440(10)64092-8
- Crowley C, Klanrit P, Butler CR. , et al. Surface modification of a POSS-nanocomposite material to enhance cellular integration of a synthetic bioscaffold. Biomaterials 2016;83:283–93. 10.1016/j.biomaterials.2016.01.005
- Leeming DJ, Larsen DV, Zhang C. , et al. Enzyme-linked immunosorbent serum assays (ELISAs) for rat and human N-terminal pro-peptide of collagen type I (PINP)—assessment of corresponding epitopes. Clin Biochem 2010;43:1249–56. 10.1016/j.clinbiochem.2010.07.025
- Chambers RC, Laurent GJ, Westergren-Thorsson G. Cadmium inhibits proteoglycan and procollagen production by cultured human lung fibroblasts. Am J Respir Cell Mol Biol 1998;19:498–506. 10.1165/ajrcmb.19.3.3242
- Chen CZ, Peng YX, Wang ZB, et al. . The Scar-in-a-Jar: studying potential antifibrotic compounds from the epigenetic to extracellular level in a single well. Br J Pharmacol 2009;158:1196–209. 10.1111/j.1476-5381.2009.00387.x
- Hong M, Wilkes MC, Penheiter SG. , et al. Non-Smad transforming growth factor-β signaling regulated by focal adhesion kinase binding the p85 subunit of phosphatidylinositol 3-kinase. J Biol Chem 2011;286:17841–50. 10.1074/jbc.M111.233676
- Bozulic L, Hemmings BA. PIKKing on PKB: regulation of PKB activity by phosphorylation. Curr Opin Cell Biol 2009;21:256–61. 10.1016/j.ceb.2009.02.002
- Islam MR, Jones SJ, Macluskey M, et al. . Is there a pAkt between VEGF and oral cancer cell migration? Cell Signal 2014;26:1294–302. 10.1016/j.cellsig.2014.02.004
- Vincent EE, Elder DJ, Thomas EC. , et al. Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer. Br J Cancer 2011;104:1755–61. 10.1038/bjc.2011.132
- Foukas LC, Berenjeno IM, Gray A. , et al. Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc Natl Acad Sci USA 2010;107:11381–6. 10.1073/pnas.0906461107
- Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014;13:140–56. 10.1038/nrd4204
- Gibbons MA, MacKinnon AC, Ramachandran P. , et al. Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis. Am J Respir Crit Care Med 2011;184:569–81. 10.1164/rccm.201010-1719OC
- Murray LA, Rosada R, Moreira AP, et al. . Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PLoS ONE 2010;5:e9683 10.1371/journal.pone.0009683
- Prasse A, Pechkovsky DV, Toews GB. , et al. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med 2006;173:781–92. 10.1164/rccm.200509-1518OC
- Stahl M, Schupp J, Jäger B, et al. . Lung collagens perpetuate pulmonary fibrosis via CD204 and M2 macrophage activation. PLoS ONE 2013;8:e81382 10.1371/journal.pone.0081382
- Marone R, Cmiljanovic V, Giese B. , et al. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 2008;1784:159–85. 10.1016/j.bbapap.2007.10.003
- Anderton MJ, Mellor HR, Bell A. , et al. Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol Pathol 2011;39:916–24. 10.1177/0192623311416259
Source: PubMed